FXR activation has been shown to decrease steatosis by inhibiting lipogenesis, reduce chemically induced hepatic inflammation and fibrosis, and maintain intestinal barrier integrity, thereby protecting the liver from inflammatory signals originating from gut bacteria [52,53]. This evidence concerns the gene NR1H4 and steatosis.